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Abstract (413 words)  
Background: Influenza illness burden is substantial, particularly among young children, older adults, 
and those with underlying conditions. Initiatives are underway to develop better global estimates for 
influenza-associated hospitalizations and deaths. Knowledge gaps remain regarding the role of 
influenza viruses in severe respiratory disease and hospitalizations among adults, particularly in 
lower-income settings.  
Methods and Findings: We aggregated published data from a systematic review and unpublished 
data from surveillance platforms to generate global meta-analytic estimates for the proportion of 
acute respiratory hospitalizations associated with influenza viruses among adults. We searched nine 
online databases (Medline, Embase, CINAHL, Cochrane Library, Scopus, Global Health, LILACS, 
WHOLIS, and CNKI, 1/1/1996-12/31/2016) to identify observational studies of influenza-associated 
hospitalizations in adults, and assessed eligible manuscripts for bias using a simplified Newcastle-
Ottawa scale for observational data. We applied meta-analytic proportions to global estimates of 
lower respiratory tract infections (LRIs) and hospitalizations from the Global Burden of Disease study 
in adults ≥20 years and by age groups (20–64 years and ≥65 years) to obtain the number of 
influenza-associated LRI episodes and hospitalizations for 2016. 
Data from 63 sources showed that influenza was associated with 14.1% (95% confidence interval 
[CI]: 12.1%–16.5%) of acute respiratory hospitalizations among all adults, with no significant 
differences by age group. The 63 data sources represent published observational studies (n=28) and 
unpublished surveillance data (n=35), from all World Health Organization regions (Africa=8, 
Americas=11, Eastern Mediterranean=7, Europe=8, Southeast Asia=11, Western Pacific=18). Data 
quality for published data sources was predominantly moderate or high quality (75%, n=56/75). 
We estimate 32,126,000 (95% CI: 20,484,000–46,129,000) influenza-associated LRI episodes and 
5,678,000 (95% CI: 3,205,000–9,432,000) LRI hospitalizations occur each year among adults. While 
adults <65 years contribute most influenza-associated LRI hospitalizations and episodes (3,464,000 
(95% CI: 1,885,000—5,978,000) LRI hospitalizations and  31,087,000 (95% CI: 19,987,000—
44,444,000) LRI episodes), hospitalizations rates were highest in those ≥65 years (437/100,000 
person-years (95% CI: 265–612/100,000 person-years)). For this analysis, published articles were 
limited in their inclusion of stratified testing data by year and age group. Lack of information 
regarding influenza vaccination of study population was also a limitation across both data sources.  
Conclusions: In this meta-analysis, we estimated that influenza viruses are associated with over five 
million hospitalizations worldwide, per year. Inclusion of both published and unpublished findings 
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allowed for increased power to generate stratified estimates, and improved representation from 
lower-income countries. Together, the available data demonstrate the importance of influenza 
viruses as a cause of severe disease and hospitalizations in younger and older adults worldwide.  
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Author Summary 
Why was this study done? 
 Every year, millions of people become infected with influenza viruses, which infect 
the airways and cause symptoms that include a fever, tiredness and weakness, 
general aches and pains, sore throat and cough.  
 Most infected individuals recover quickly, but some develop more severe illness such 
as pneumonia, and may require hospitalization. 
 Influenza vaccination can prevent infections and severe disease, but decisions on 
how to prioritize risk groups, particularly in limited-resource settings, require a robust 
evidence base, including global, regional, and local data.     
What did the researchers do and find? 
 We conducted a systematic review to identify published articles on influenza-
associated respiratory disease in hospitalized adults. 
 We then aggregated the data from these articles with data collected by hospital-
based influenza surveillance, to calculate a pooled estimate of the proportion of 
adults hospitalized with respiratory disease who are positive for influenza. 
 Through this approach, we estimated that influenza was associated with 14% of 
acute respiratory hospitalizations among adults worldwide. 
 This equates to over five million influenza-associated hospitalizations per year, with 
highest rates among those 65 years and older.  
What do these findings mean? 
 Estimating the disease burden of influenza allows researchers and policymakers 
better understand its global impact across different target groups and allow 
comparisons with other causes of morbidity and mortality.  
 As global populations age, the importance of vaccinating adults, particularly older 
adults, is likely to increase.  
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Introduction 
Influenza viruses contribute substantially to respiratory disease worldwide, including severe 
lower respiratory tract illnesses, hospitalizations, and deaths. The highest rates of severe 
influenza-associated disease and hospitalization are typically reported among those at the 
extremes of age [1-4] and those with underlying health conditions [5]. To reduce the burden 
of influenza, the World Health Organization (WHO) Strategic Advisory Group of Experts 
(SAGE) recommends that countries initiating or expanding an influenza vaccination program 
prioritize pregnant women, children aged 6–59 months, adults ≥65 years, individuals with 
high-risk conditions, and healthcare workers [6]. During the COVID-19 pandemic, SAGE has 
also released interim recommendations prioritizing healthcare workers and older adults for 
influenza vaccination [7] . 
Global influenza burden estimates generated to date include all-age estimates of 
hospitalizations and mortality, as well as age-specific estimates for paediatric 
hospitalizations [8-10]. Important gaps in knowledge remain about the burden of influenza-
associated severe respiratory disease and hospitalizations in adults, particularly in lower-
resource settings, because of the dearth of denominators for incidence calculations [11]. The 
objective of these analyses was to generate a global estimate of the annual number of 
respiratory hospitalizations and lower respiratory tract infections (LRIs) associated with 
influenza viruses among adults ≥20 years worldwide, utilizing published findings and 
unpublished laboratory-confirmed data from a global network of influenza surveillance 
partners.  
Methods 
Research objective and data sources 
Our a priori research objective was to estimate the proportion of adult respiratory 
hospitalizations that tested positive for influenza (“proportion positive”) as a summary 
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statistic. We generated this estimate using two sources of data: a systematic review of the 
literature and unpublished respiratory inpatient surveillance data from a global working group 
of partners. We then applied the summary meta-analytic proportion positive to global 
estimates of adult LRI episodes and hospitalizations available for adults ≥20 years.  
Systematic literature review: search strategy and selection criteria 
We searched nine online databases (Medline, Embase, CINAHL, Cochrane Library, Scopus, 
Global Health, LILACS, WHOLIS, and CNKI) for articles published in any language from 
January 1, 1996 to December 31, 2016 to identify studies of influenza-associated 
hospitalizations in adults. Keywords included “influenza” and terms related to hospitalization 
(e.g., “hospital*,” “inpatient”) (Supplementary Table 1). Titles and abstracts of all articles 
identified were screened for inclusion in the analysis by a member of the review team (KL, 
RP, JK, MW, EAB, MAW) with support from native language speakers as needed. Chinese-
language articles were screened by native Mandarin speakers (ZS and ZR). A random 
subset (25%) of articles were screened by a second reviewer for validation. An article was 
included for full-text review if at least one reviewer flagged it as potentially eligible. The 
inclusion criteria were: 1) an original study on human subjects; 2) laboratory testing for both 
influenza A and B viruses, with description of diagnostic method(s) used; 3) a minimum of 12 
months’ continuous data; 4) a specified case definition or other clear criteria for systematic 
specimen collection and testing; 5) inclusion of hospitalized patients; 6) inclusion of the 
number of cases from whom clinical specimens were collected and the number found 
positive; and 7) a minimum of 50 adults >18 years of age (or an adult population, as 
described by authors) tested for influenza across the duration of the study.  
We excluded studies that described nosocomial influenza infections or included data from 
calendar year 2009 (the initial wave of influenza A[H1N1]pdm09 virus circulation) in a 
manner that could not be separated from data from other years, since both influenza 
epidemiology and testing practices were atypical during this period. Although the influenza 
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A(H1N1)pdm09 pandemic period continued into 2010, this was often second-wave 
circulation and was not excluded from the analysis. For titles and abstracts meeting criteria, 
full-text articles were assessed independently by two members of the review team. Any 
discrepant decisions on full-text articles were first discussed between the two reviewers; 
those that could not be resolved (n=2) were adjudicated by a third reviewer (MAW).  
From each eligible article, we abstracted the following data elements: 1) the total number of 
inpatients tested and total positive for influenza by age group and influenza type and 
subtype where available, 2) location and timeframe of data collection, 3) the case definition 
and diagnostic test(s) used, 4) the proportion of the study population with any underlying 
conditions (as defined by the paper), and 5) influenza vaccination coverage in the study 
population. We recorded whether the study population was a “special population,” defined as 
a selection of participants not representative of all inpatients (e.g., intensive care unit 
patients, or those with chronic obstructive pulmonary disease [COPD]). WHO region, World 
Bank income category (low, lower-middle, upper-middle, or high income), and pneumococcal 
conjugate vaccine (PCV) introduction status were assigned for each dataset, based on the 
country and start year of data collection [12, 13]. Quality of evidence for each published 
paper was evaluated on a simplified Newcastle-Ottawa scale, as described previously [8, 
14]. Key variables (number tested and positive, laboratory method used, and quality score) 
were abstracted by two independent reviewers. We did not pre-register the protocol for this 
systematic review. A full list of eligible published articles with key abstracted data, and a 
PRISMA checklist for systematic reviews [15], are provided in Supplementary Materials 
(Supplementary Table 2, Supplementary Checklist 1).  
GRIPP working group  
To supplement data from published studies, we established a working group, Global 
Respiratory Hospitalizations – Influenza Proportion Positive (GRIPP), which compiled recent, 
typically unpublished data through 2016 from surveillance platforms conducting systematic 
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inpatient surveillance for influenza. Eligible surveillance platforms included those conducting 
systematic year-round inpatient testing using any acute respiratory case definition (e.g., 
severe acute respiratory infection [SARI], community-acquired pneumonia [CAP]) for at least 
12 consecutive months and that tested at least 50 adult inpatients over the duration of the 
study. Minimum of 50 samples was selected to reduce within-study variance and remove 
undue influence of very small studies. We contacted seventy-three partners, of whom 37 
(51%) had eligible adult data and agreed to participate in the GRIPP working group. We 
collected the following data in a standardized form: the number of persons tested and 
positive for influenza by calendar year and age group (18–64 years and ≥65 years), the total 
number of inpatient sites, case definition used, and any participant selection procedures. 
Patient comorbid conditions and influenza vaccination status were not frequently reported in 
partner surveillance platforms, and were not collected on the standardized form. If 
surveillance data were also represented in a manuscript identified through systematic 
review, the working group dataset was used, and the published article was excluded as a 
duplicate source. Working group data were not scored for quality in the same manner as 
published articles, but were reviewed for completeness and internal consistency of primary 
results. Influenza virus detections were reported by type and A subtypes where available; 
however, as influenza B virus lineage testing was rarely conducted during the study period, it 
was not included in the current analyses. 
Statistical analysis 
We explored all data from both published and unpublished sources in the univariate analysis 
of median proportion positive by categorical variables (such as diagnostic test used, case 
definition, WHO region, and country income classification). We tested for differences in 
frequencies across groups using chi-square. Since the proportion of respiratory samples 
testing positive for influenza was not normally distributed, we estimated median values and 
interquartile ranges (IQRs), and used Kruskal-Wallis non-parametric ANOVA to compare the 
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summary proportion positive per dataset/study across groups. We used a p-value of <0.05 
as our threshold for significance. 
To minimize variability observed among data sources in the univariate analysis, we limited 
the meta-analysis to data derived from gold-standard RT-PCR diagnostic testing and 
excluded all studies of special populations to estimate the proportion of adult respiratory 
hospitalizations positive for influenza. To derive meta-analytic estimates of proportion 
positive, we used a log-binomial mixed model with a random effect for data source that 
allowed for inclusion of multiple years of data within a single data source [8]. I2 was 
calculated as variance across datasets as a percentage of total variance in each model. We 
generated overall, age-stratified (20–64 and ≥65 years), and influenza A and B virus-specific 
proportion positive estimates. Virus type-specific models were restricted to datasets with at 
least one type-specific positive sample.  
Overall and age-specific meta-analytic estimates of proportion positive were multiplied by 
LRI hospitalization and LRI episode estimates for adults ≥20 years, which were from the 
Global Burden of Disease (GBD) 2017 study [10], obtained for calendar year 2016 for this 
analysis. The GBD study models incidence of lower respiratory infection episodes and 
hospitalizations at a global and regional level, by age group, using a Bayesian meta-
regression tool. Confidence intervals for our multiplied estimates of number of influenza-
associated events were created through a Monte Carlo resampling process that assumed 
normal distribution for denominators and binomial distributions for the modelled proportion 
positive estimates, using 95% confidence intervals as lower and upper bounds, with 5,000 
iterations. We calculated rates by dividing the above estimates by 2016 global population 
[16]. Post-hoc sensitivity analyses were conducted to explore patterns in heterogeneity (I2) of 
the pooled proportion positive and percent change in the estimated number of 
hospitalizations by stratifying for key covariates. All statistical analyses were conducted in R 
version 3.5.2, with package “lme4” for mixed models [17, 18]. 
Global Adult Hospitalizations for Influenza 
 
Ethical approval was not required for this study. 
Results 
The systematic literature search identified 18,945 unique articles published between January 
1996 and December 2016, describing data collected from 1982 through 2016. An additional 
21 articles were identified outside the search through consultation with subject-matter 
experts and review of references. Of these 18,966 articles, we reviewed 1,158 full-text 
articles; 75 met the inclusion criteria and were abstracted for the descriptive analysis (Figure 
1). Combining these with the 37 GRIPP working group surveillance datasets, we included 
112 unique influenza data sources from 55 countries across all six WHO regions. Compared 
with published articles, surveillance datasets were more likely to use RT-PCR as the primary 
method of diagnosis (n=35/37, 95% vs. n=38/75, 51%, p<0.001) and more likely to use SARI 
a WHO-recommended case definition for severe influenza disease [19] as case definition 
(78% vs. 8%, p<0.001). Surveillance datasets were also more commonly from low- and 
lower-middle income countries, compared with published articles (67% vs. 14%, p<0.001). 
Approximately 57% of published articles presented <2 years of data, versus 8% of 
surveillance datasets (p<0.001). Special populations were the specific focus of 27% 
(n=20/75) of published articles, and none of the surveillance datasets (Table 1). Frequency 
of comorbid conditions was reported for 47 (63%) of 75 published articles, with a range of 
25% to 100% of patients having one or more conditions. Influenza vaccination status of 
patients was only reported by five articles; vaccine coverage ranged between 7% and 48% .  
Among all data sources (n=112), the median percent of respiratory samples that were 
influenza positive among adult patients <65 years was similar to that among those ≥65 years 
(15%, IQR 9–21% vs. 13%, IQR 8–17%, respectively; p=0.280). The median percent 
positive was higher among surveillance data compared to published articles (15%, IQR 10–
20%, vs. 10%, IQR 6–17%, p=0.011). The median percent positive was higher among 
middle-income countries than low- or high-income countries (p=0.035). Case definition was 
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also influential, with higher values among studies using SARI or LRI compared to those 
using acute respiratory infection (ARI) or pneumonia. The percent of patients positive for 
influenza was not associated with diagnostic test used (Supplementary Table 3). When we 
restricted the data to the subset of studies that were included in the meta-analysis—i.e., 
those using RT-PCR data (excluding special populations), shown in Table 2 —the median 
proportion positive differed only by case definition as indicated by post hoc non-parametric 
pairwise testing (Dunn’s test with Bonferroni correction) which identified a significant 
difference between pneumonia-based estimates and SARI-based estimates (p=0.0047).  
Data by year and influenza A virus subtype were primarily available from post-2009 
pandemic surveillance conducted by the GRIPP working group (Figure 2). While different 
virus types and subtypes predominated from year to year within individual datasets, the 
yearly median percent positive across datasets showed influenza A viruses were detected 
approximately three times more frequently than influenza B viruses, with generally equal 
frequency of influenza A(H1N1) and influenza A(H3N2) viruses in any given year. An 
increasing trend was seen in influenza A (overall and both subtypes), but not influenza B 
during this time. 
The primary meta-analysis model (n=63 datasets) found influenza to be associated with 
14.1% (95% CI: 12.1–16.5%) of acute respiratory hospitalizations (all adults). Influenza A 
viruses were associated with an estimated 10.6% (95% CI: 8.9–12.5%) of these episodes 
and influenza B viruses with 3.5% (95% CI: 2.8–4.3%). Applying the overall percent 
influenza-positive to estimates of hospitalized and total LRI episodes resulted in a total of 
5,678,000 (95% CI: 3,205,000–9,432,000) influenza-associated LRI hospitalizations and 
32,126,000 (95% CI: 20,484,000–46,129,000) influenza-associated LRI episodes in persons 
≥20 years globally. Using age-specific proportion positive estimates, this equated to 
3,464,000 (95% CI: 1,885,000–5,978,000) influenza-associated hospitalizations among 
adults 20–64 years and 2,831,000 (95% CI: 1,716,000–3,969,000) influenza-associated 
hospitalizations among adults ≥65 years (Table 3). From these estimates, we calculated a 
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rate of 80 (95% CI: 44–139) hospitalizations/100,000 population among adults <65 years 
and 437 (95% CI: 265–612) hospitalizations/100,000 population among older adults. By 
virus type, we estimated 4,264,000 (95% CI: 2,185,000–7,353,000) influenza A–associated 
and 1,408,000 (95% CI: 322,000–3,034,000) influenza B–associated hospitalizations each 
year, as well as 24,126,000 (95% CI: 13,880,000–36,677,000) influenza A–associated and 
7,966,000 (95% CI: 1,650,000–15,426,000) influenza B–associated LRI episodes. Regional 
estimates are presented in Supplementary Table 4. Additional model data and sensitivity 
analyses are presented in Supplementary Table 5. A forest plot of findings by dataset is 
presented in Supplementary Figure 1. 
Discussion 
We estimated that seasonal influenza viruses were associated with 14% of acute lower 
respiratory disease among hospitalized adults. In 2016, this equated to 5.7 million influenza-
associated LRI hospitalizations and 32.1 million LRI episodes globally. The majority of 
hospitalizations and episodes occurred among younger adults, although influenza-
associated hospitalization rates were five times higher among older adults. Three-quarters of 
episodes (24 million) were associated with influenza A viruses of any subtype, and one-
quarter (8 million) were associated with influenza B viruses.  
These estimates are consistent with, or slightly higher than, existing global estimates of 
influenza morbidity and mortality. Our model adds to the existing knowledge by providing an 
estimate focused specifically on adult populations, adding a large amount of additional 
influenza-specific data from unpublished surveillance data over several years from a diverse 
range of countries where publications are often no available, and allowing for validation and 
triangulation across models. The 2017 GBD Study found that influenza was associated with 
9.5 million LRI hospitalizations worldwide among all age groups, with a majority of these 
occurring among children 19 years and younger. This estimate was based on an attributable 
fraction estimate for all ages of 8.5%, derived from a systematic literature review of 
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published studies, but was lower than our estimate for adults (14%), as well as our previous 
estimate for older children (16%) [8, 10]. Their approach might underestimate the attributable 
fraction of influenza among adults because of the inclusion of paediatric patients, who are 
less likely to test positive for influenza. The attributable fraction used in the GBD analysis 
also included data derived from less-sensitive diagnostic assays (i.e., ELISA) in addition to 
RT-PCR–diagnosed influenza [20].  
By comparing our estimated LRI episodes and hospitalizations to published estimates of 
global influenza mortality, we are also able to validate our estimated outcomes. Recent 
estimates suggest that influenza is associated with 291,243–645,832 deaths per year [9]. 
Assuming the majority of deaths occur among adults, and using the upper bound of their 
estimate, this would translate to 11% of influenza-associated hospitalizations and 2% of 
influenza-associated LRI episodes, which are consistent with parameters from the US 
burden of disease pyramid for influenza [21].  
This analysis is subject to several limitations. Our model summarizes the magnitude of 
influenza-associated hospitalizations across many years to determine the proportion that are 
influenza-associated in any one year. However, the proportion of respiratory disease caused 
by influenza in a given setting or year can be affected by a wide range of factors, such as 
specimen type, case definition, influenza and pneumococcal vaccine use, characteristics of 
predominating influenza viruses, and trends in circulation of other pathogens. We attempted 
to understand and control for these factors in the current analysis through our inclusion 
criteria (sampling process used, year-round diagnostic testing) and stratified analysis (by 
case definition and other factors). The proportion of patients with respiratory disease who 
are hospitalized is also affected by many factors, such as access to care and health-seeking 
behaviour; diagnostic, admission, and referral practices; age; and underlying health status, 
which likely differ by study site. An additional challenge for this analysis was the relatively 
limited amount or lack of stratified data (by year, age group, virus subtype, presence of 
underlying conditions, region, vaccination history) from both published and unpublished data 
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sources to make for robust stratified analyses (e.g. by region). Further, laboratory diagnosis 
of influenza in a case of adult LRTI may not mean that influenza infection was the cause of 
hospitalization, as we did not account for other pathogens or underlying factors.Finally, our 
estimates for LRI episodes are generated with a proportion influenza-positive derived from 
hospitalized illnesses. Total LRI episodes include illnesses that may or may not be 
hospitalized; in lower-income settings access to hospital services can be limited, therefore 
individuals with illnesses who do not seek care are likely to share similar characteristics with 
those who do. The proportion associated with influenza may be similar between those who 
are and are not hospitalized in these settings. Moreover, previous global analyses [10] 
indicate that non-severe LRI is often more likely to be influenza-positive than severe LRI, 
and thus applying the hospitalized percent positive to potentially milder non-hospitalized LRI 
cases suggests that we may have underestimated the true burden of total influenza-
associated LRI episodes worldwide.  
Conclusions 
The burden of severe influenza-associated disease and hospitalizations among adults 
worldwide is substantial. While older adults, young children, pregnant women, and those 
with chronic illness are already recommended as target groups for vaccination by WHO, 
influenza vaccine uptake is low globally, and the standard-dose, inactivated influenza 
vaccines predominantly used in these settings may have a lower effectiveness in key 
populations such as older adults, compared to younger adult populations [22]. Efforts to 
improve influenza vaccines (e.g., via high-dose or adjuvanted formulations) and expand 
vaccination programs in low- and middle-income countries could lead to more routine 
vaccination and thus increase protection against severe influenza disease [23-25]; however, 
these initiatives require substantial investment of time and resources.  
Given these challenges, and variations in incidence within and between nations and regions, 
high-quality surveillance data will continue to play a pivotal role in informing influenza 
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prevention and control measures, particularly in elucidating influenza virus infection’s role as 
a cause of severe respiratory disease and hospitalizations among adults. Moreover, with the 
emergence of SARS-CoV-2 this study emphasises the critical importance of unbiased 
surveillance using standard case definitions in a wide range of settings in understanding 
global and regional impact of respiratory diseases. 
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Table 1. Description of published studies and Global Respiratory Hospitalizations –Influenza Proportion Positive (GRIPP) 
surveillance datasets summarizing influenza-associated respiratory hospitalizations among adults, 1996–2016 
 Published studies, n=75 Surveillance datasets, n=37 
 
  n % n % p-value 
Age group      
Adults <65 years* 14 19% 36 97% <0.001 
Adults ≥65 years 32 43% 16 43% 0.95 
All adults 75 100% 37 100%  
Study duration in years     <0.001 
1 to 2 43 57% 3 8%  
3 to 4 31 41% 14 38%  
5+ 1 1% 20 54%  
Study year (Range)  (1982–2016)  (2005–2016)  
Timeframe   <0.001 
Pre-2009 data only 45 60% 0 0%  
Post-2009 data 30 40% 31 84%  
Both pre- and post-2009 data 0 0% 6 16%  
Total number of specimens tested     <0.001 
50–99 12 16% 1 3%  
100–499 48 64% 7 19%  
500–999 9 12% 5 14%  
1000+ 6 8% 24 65%  
Diagnostic Test     <0.001 
RT-PCR only 23 31% 17 46%  
Immunofluorescence only 12 16% 0 0%  
Serological assay only 13 17% 0 0%  
Multiple tests, including RT-PCR 18 24% 20 54%  
Multiple tests, excluding RT-PCR 6 8% 0 0%  
Other† 3 4% 0 0%  
Case definition     <0.001 
Acute respiratory infection (ARI) 6 8% 1 3%  
Lower respiratory infection (LRI) 3 4% 5 14%  
Pneumonia 32 43% 0 0%  
Severe acute respiratory infection 
(SARI) 6 8% 29 78% 
 
Other‡ 28 37% 2 5%  
Special population¶     <0.001 
Yes 20 27% 0 0%  
No 55 73% 37 100%  
World Health Organization region     <0.001 
Africa  1 1% 8 22%  
Americas 11 15% 7 19%  
Eastern Mediterranean 4 5% 4 11%  
Europe 22 29% 1 3%  
Southeast Asia 5 7% 9 24%  
Western Pacific 32 43% 8 22%  
World Bank income level     <0.001 
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Low 1 1% 9 24%  
Lower-middle 10 13% 16 43%  
Upper-middle 24 32% 7 19%  
High 40 53% 5 14%  
Quality score (published studies only)§      
0 2 3%    
1 17 23%    
2 36 48%    
3 20 27%      
Included in meta-analysis     <0.001 
Yes 28 37% 35 95%  
No 47 63% 2 5%  
*Gaps in age-specific estimates due to lack of outcome data stratified by age group.  
† Includes rapid immunochromatographic assay (n=2), virus culture (n=1) 
‡ Includes acute exacerbation of chronic obstructive pulmonary disease (COPD) (n=14), respiratory 
hospitalization (acute or non-acute) (n=10), acute exacerbation of asthma (n=3), acute febrile illness (n=2), 
intubation among intensive care unit (ICU) patients (n=1), acute respiratory distress syndrome (ARDS) (n=1), 
ICD-codes consistent with influenza (n=1), and acute coronary syndrome with recent influenza-like illness  
(n=1). 
¶ Includes studies of populations with COPD (n=10), hospitalised in the ICU only (n=3), immunocompromising 
conditions (n=1), asthma (n=1), heart disease (n=1), or in the military (n=1). 
§ Quality of included articles was assessed using a simplified Newcastle-Ottawa Scale [9, 15]. Possible quality 
score from 0 (lowest) to 3 (highest).
 
 
Table 2. Median number of specimens tested and percent positive for influenza, by age group, study design, and population 

















 p value 
All adults  63 510 225 2,092 13% 8% 19%  
Age group*          
18-64 years 41 867 341 2,759 16% 11% 21% 0.17 
65+ years 38 198 81 890 14% 9% 17%  
Data source         
Surveillance 35 1,376 542 3,775 15% 10% 20% 0.089 
Published 28 225 120 349 10% 7% 18%  
Timeframe         
Pre-2009 data 14 191 124 242 9% 8% 12% 0.097 
Post-2009 data 45 987 328 2,818 15% 9% 20%  
Pre- & post-2009 data 4 5,948 2,581 9,527 10% 10% 13%  
Case definition         
Acute respiratory infection (ARI) 6 254 126 279 10% 4% 13% 0.0064 
Lower respiratory infection (LRI) 7 1,158 513 6,140 13% 11% 15%  
Pneumonia 12 182 120 258 8% 6% 10%  
Severe acute respiratory 
infection (SARI) 33 
1,720 426 3,222 17% 11% 21% 
 
Other† 5 510 256 582 10% 9% 17%  
World Health Organization region         
Africa  8 1,490 491 1,797 9% 6% 11% 0.071 
Americas 11 328 210 4,081 13% 7% 18%  
Eastern Mediterranean 7 987 361 2,743 20% 20% 22%  
Europe 8 191 134 262 9% 7% 11%  
Southeast Asia 11 1,130 456 2,573 14% 11% 18%  
Western Pacific 18 485 259 2,458 15% 10% 19%  
World Bank income level         
Low 9 1,253 565 1,766 12% 11% 14% 0.14 
Lower-middle 20 785 312 2,952 16% 10% 21%  
Upper-middle 16 467 237 1,737 15% 9% 21%  
High 18 294 188 1,822 10% 7% 15%  
*Gaps in age-specific estimates due to lack of outcome data stratified by age group.  
† Includes respiratory hospitalization (acute or non-acute) (n=4), ICD codes consistent with influenza (n=1).
 
 















*All-cause estimates are derived from Global Burden of Disease project, adapted for 2016, among individuals 20 years and older.  
**Percent positive and number of datasets from meta-analysis 
 
 









events (95% CI) 
[thousands] 
Rate per 100 000 
population (95% CI) 
All adults–any influenza      
Hospitalized LRI episodes 40,226 (25,810–59,569) 
14.1% (12.1%–16.5%) 63 
5,678 (3,205—9,432)   115 (65—190) 
LRI episodes  227,603 (190,403—268,571) 
32,126 (20,484 – 
46,129) 
649 (414—931) 
All adults–influenza A      
Hospitalized LRI episodes 40,226 (25,810–59,569) 
10.6% (8.9%–12.5%) 51 
4,264 (2,185—7,353) 86 (44—148) 
LRI episodes 227,603 (190,403—268,571) 
24,126 (13,880—
36,677) 487 (280—740) 
All adults–influenza B      
Hospitalized LRI episodes 40,226 (25,810–59,569) 
3.5% (2.8%–4.3%) 46 
1,408 (322—3,034) 28 (7—61) 
LRI episodes 227,603 (190,403—268,571) 7,966 (1,650—15,426) 161 (33—311) 
Adults 20–64 years–any influenza      
Hospitalized LRI episodes   20,939 (12,894—32,704) 
16.5% (13.7%–19.8%) 41 
 3,464 (1,885—5,978)  80 (44—139) 
LRI episodes    187,893 (155,794—223,148) 
 31,087 (19,987—
44,444)  722 (464—1,032) 
Adults ≥65 years–any influenza      
Hospitalized LRI episodes 19,287 (12,916–26,866) 
14.7% (12.7%–16.8%) 38 
2,831 (1,716–3,969)  437 (265–612) 
LRI episodes   39,709 (34,609–45,423) 5,830 (4,927–6,740) 899 (760–1,040) 
 
 
Figure 1. Flow diagram for systematic review process (separate file) 
Figure 2. Median proportion of adult respiratory samples testing positive for influenza virus by year and virus type/subtype, 
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